Skip to main content
Rachel Rau, MD, Pediatric Hematology & Oncology, Seattle, WA

RachelERauMD

Pediatric Hematology & Oncology • Seattle, WA

Associate Professor, Pediatrics, University of Washington/Seattle Children’s Hospital

Join to view full profile

Dr. Rau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rau's full profile

Already have an account?

  • Office

    4800 Sand Point Way NE
    Suite 1220
    Seattle, WA 98105
    Phone+1 206-884-4464

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2006 - 2010
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pediatrics, 2003 - 2006
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2003

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 2012 - 2024
  • MD State Medical License
    MD State Medical License 2006 - 2013
  • American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia
    Rachel E. Rau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or...
    Rachel E. Rau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia
    Rachel E. Rau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024

Press Mentions

  • With Chemo, Blinatumomab Boosts DFS in Pediatric B-ALL
    With Chemo, Blinatumomab Boosts DFS in Pediatric B-ALLDecember 8th, 2024
  • Blincyto® (Blinatumomab) Added to Chemotherapy Significantly Improves Survival in Newly Diagnosed Pediatric Patients with B-cell Precursor Acute Lymphoblastic Leukemia (B-all)
    Blincyto® (Blinatumomab) Added to Chemotherapy Significantly Improves Survival in Newly Diagnosed Pediatric Patients with B-cell Precursor Acute Lymphoblastic Leukemia (B-all)December 8th, 2024
  • New Standard for Newly Diagnosed Pediatric B-cell Acute Lymphoblastic Leukemia
    New Standard for Newly Diagnosed Pediatric B-cell Acute Lymphoblastic LeukemiaDecember 7th, 2024
  • Join now to see all

Dr. Rachel Rau, Dr. Rachel Rau, MD, Dr. R Rau, Dr. Rachel E Rau